Pipeline Full, Dividend Secure, Says Glaxo CFO
Simon Dingemans, CFO of GlaxoSmithKline, discusses the company's bid for Human Genome, Obamacare and the company's growing emerging-market business.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
